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Abstract
Background: In the eukaryotic cell the cAMP-dependent protein kinase (PKA) is a key enzyme in
signal transduction and represents the main target of the second messenger cAMP. Here we
describe the design, synthesis and characterisation of specifically tailored cAMP analogs which can
be utilised as a tool for affinity enrichment and purification as well as for proteomics based analyses
of cAMP binding proteins.
Results: Two sets of chemical binders were developed based on the phosphorothioate derivatives
of cAMP, Sp-cAMPS and Rp-cAMPS acting as cAMP-agonists and -antagonists, respectively. These
compounds were tested via direct surface plasmon resonance (SPR) analyses for their binding
properties to PKA R-subunits and holoenzyme. Furthermore, these analogs were used in an affinity
purification approach to analyse their binding and elution properties for the enrichment and
improvement of cAMP binding proteins exemplified by the PKA R-subunits. As determined by SPR,
all tested Sp-analogs provide valuable tools for affinity chromatography. However, Sp-8-AEA-
cAMPS displayed (i) superior enrichment properties while maintaining low unspecific binding to
other proteins in crude cell lysates, (ii) allowing mild elution conditions and (iii) providing the
capability to efficiently purify all four isoforms of active PKA R-subunit in milligram quantities within
8 h. In a chemical proteomics approach both sets of binders, Rp- and Sp-cAMPS derivatives, can be
employed. Whereas Sp-8-AEA-cAMPS preferentially binds free R-subunit, Rp-AHDAA-cAMPS,
displaying antagonist properties, not only binds to the free PKA R-subunits but also to the intact
PKA holoenzyme both from recombinant and endogenous sources.
Conclusion: In summary, all tested cAMP analogs were useful for their respective application as
an affinity reagent which can enhance purification of cAMP binding proteins. Sp-8-AEA-cAMPS was
considered the most efficient analog since Sp-8-AHA-cAMPS and Sp-2-AHA-cAMPS, demonstrated
incomplete elution from the matrix, as well as retaining notable amounts of bound protein
contaminants. Furthermore it could be demonstrated that an affinity resin based on Rp-8-AHDAA-
cAMPS provides a valuable tool for chemical proteomics approaches.
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Background
The cAMP-dependent protein kinase (PKA) is a key regu-
lator protein in eukaryotic signal transduction and is
involved in several cellular processes during growth and
development. Via phosphorylation of its substrate pro-
teins PKA controls metabolic processes, cAMP mediated
gene expression, cell differentiation and/or apoptosis [1].
The enzymatic activity of the PKA catalytic (C) subunit is
controlled by a set of four different regulatory (R) subunit
isoforms, i.e. type I and type II, both with two isoforms (α
and β) each. Thus, in its inactive state PKA forms a heter-
otetrameric holoenzyme complex (R2C2), containing an
R-subunit dimer and two C-subunit monomers. The PKA
holoenzyme is activated upon cooperative binding of four
molecules of the second messenger cAMP to the R-subu-
nits, thus releasing the now active C-subunits [2]. The
expression pattern of single PKA isoforms as well as the
isoform specific composition of the holoenzyme and tis-
sue specific distribution of PKA isoforms allows a tight
regulation of the catalytic activity of PKA. In turn, PKA
provides an important model system for kinases, allowing
investigation of the molecular mechanisms of kinase
function as well as the development of tools for diagnostic
purposes which in turn enables their use as biomarkers
[3].
Historically, purification of PKA holoenzyme from bio-
logical material was performed via anion exchange chro-
matography (DEAE, [4]); later, a second step based on
affinity purification utilising cAMP resins was added [5,6].
However, most strategies so far resulted in either partly
degraded or insoluble protein with limited yield. There-
fore we set out to design novel cAMP affinity matrices for
simple and rapid purification of cAMP binding proteins.
These resins should provide a chemical tool that targets
proteins containing the conserved cAMP binding
domains, specifically PKA R-subunits while fulfilling the
following criteria required for efficient affinity binders:
1. Purify high quantities of selected protein of interest;
2. yield functionally active protein;
3. provide a purification procedure with mild but efficient
elution conditions while retaining high yields of protein;
4. obtain nucleotide-free proteins which can easily be
used for further interaction studies and biochemical
assays;
5. provide an easy-to-use procedure applicable in chemi-
cal proteomics.
In addition to cAMP's role as a general activator of all
holoenzyme isoforms, with PKA representing the main
intracellular effector of cAMP, there are still other targets
of cAMP like nucleotide-gated ion channels [7], cAMP
degrading phosphodiesterases [8] or Epac, the cAMP-reg-
ulated guanine nucleotide-exchange factor for Rap 1 and
2 [9], all containing one or more highly conserved cyclic
nucleotide binding (CNB) domains [10].
PKA R-subunits and specific components of the cAMP sig-
nalling network can be precisely targeted from complex
protein mixtures using highly specific cAMP analogs cov-
alently coupled to agarose beads. Generally, two groups of
chemical tools are used for the affinity purification of
functional complexes: agonist and antagonist binders
(Fig. 1A). Agonist binders are synthetic cyclic nucleotides
which bind the R-subunits that are complexed with inter-
action partners (e.g. AKAPs), however, these agonists
cause the PKA holoenzyme to dissociate. Antagonist bind-
ers, interacting preferentially with the intact, non dissoci-
ated PKA holoenzyme, can be utilised to identify
interaction partners that bind to the entire complex
(R2C2), including proteins interacting with the C-subu-
nits.
In the present study several cyclic nucleotide analogs were
synthesised and optimised for their binding properties to
the respective components of the PKA system using an
iterative approach based on direct SPR binding studies.
Subsequently, these cAMP analogs were coupled to a solid
support and tested for binding and elution in a one step
purification procedure probing all four recombinantly
expressed R-subunit isoforms. Furthermore, we tested
optimised cyclic nucleotides analogs for their application
in a chemical proteomics approach addressing either the
R-subunits or the intact PKA holoenzyme complex along
with physiological interaction partners derived from ani-
mal tissue.
Results
In previous studies, hundreds of cyclic nucleotides were
developed and characterised regarding their binding abil-
ity to proteins containing cyclic nucleotide binding (CNB)
domains [11-14].
Improved cAMP analogs as novel tools for PKA R-subunit 
purification
For our developments we used optimised binders based
on Sp-cAMPS (Fig. 1A left panel, 1B), a cAMP analog
where the axial exocyclic oxygen atom of the cyclic phos-
phate is replaced by a sulphur atom, resulting in an
approximately 10-fold reduced affinity towards the R-sub-
unit when compared to cAMP alone [15-17]. In order to
couple Sp-cAMPS to a solid phase, analogs with different
spacers in positions 2 or 8 of the adenine base (Sp-8-AEA-
cAMPS, Sp-8-AHA-cAMPS, Sp-2-AHA-cAMPS, Fig. 1B)
were designed and synthesised. Two complementary strat-BMC Chemical Biology 2009, 9:3 http://www.biomedcentral.com/1472-6769/9/3
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egies were combined for the characterisation of improved
binders for PKA R-subunit purification. In initial kinetic
studies, surface plasmon resonance (SPR) was employed
and selected cAMP analogs were immobilised on a sensor
chip and the association and dissociation patterns of all
four R-subunit isoforms were analysed in detail. In an
additional approach, these cAMP analogs were coupled to
agarose beads and their ability for affinity purification of
R-subunits was studied via pull down experiments. In
both sets of experiments, 8-AHA-cAMP and 8-AEA-cAMP
were used as controls, since they represent conventional
cAMP analogs which have been commonly applied for
purification of PKA R-subunits or for interaction studies
in previous reports [6,12,18-29].
SPR binding studies
8-AEA-cAMP, 8-AHA-cAMP, Sp-8-AEA-cAMPS, Sp-8-AHA-
cAMPS and Sp-2-AHA-cAMPS were covalently coupled to
a sensor surface using NHS/EDC chemistry and the asso-
ciation and dissociation patterns of the four different R-
subunit isoforms (RIα, RIβ, RIIα, RIIβ) were analysed
using a Biacore 2000 instrument (Fig. 2). All four R-subu-
nit isoforms showed fast association behaviour when
binding to the immobilised cAMP analogs. No notable
dissociation could be detected when switching the instru-
ment to buffer, thus indicating a stable interaction
between the R-subunit and the immobilised cAMP ana-
logs (Fig. 2F). When adding cGMP (3 mM) during the dis-
sociation phase the dissociation behaviour from an
Chemical structures of cyclic nucleotides Figure 1
Chemical structures of cyclic nucleotides. (A) Model of the bovine RIα subunit (PDB-ID 1RGS) with bound agonist (Sp-
8-AHA-cAMPS, left) and antagonist (Rp-8-AHA-cAMPS, right). The figure was created using standard settings in VMD 1.8.4 
[58]. Chemical structures of Sp-cAMPS (B) and Rp-cAMPS (C) analogs. Arrows indicate positions of attached linkers.
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Interaction of R-subunit isoforms with immobilised cAMP analogs investigated by SPR Figure 2
Interaction of R-subunit isoforms with immobilised cAMP analogs investigated by SPR. Binding of all four R-subu-
nit isoforms (100 nM) to immobilised 8-AEA-cAMP (A), 8-AHA-cAMP (B), Sp-8-AEA-cAMPS (C) and Sp-8-AHA-cAMPS (D) 
Sp-2-AHA-cAMPS (E) using a flow rate of 10 μL/min in buffer A containing 0.005% P20. Association and dissociation of hRIα 
(blue), hRIβ (red), hRIIα (green) and rRIIβ (black) were monitored for 5 and 10 min, respectively. The dissociation was moni-
tored in the presence of 3 mM cGMP. (F) hRIα binding to five different cAMP analogs. 100 nM hRIα was injected to immobi-
lised 8-AHA-cAMP (red), 8-AEA-cAMP (orange), Sp-2-AHA-cAMPS (green), Sp-8-AEA-cAMPS (blue) and Sp-8-AHA-cAMPS 
(black). Dissociation was initiated either by buffer A containing 0.005% P20 (dotted lines) or by 3 mM cGMP in the same buffer 
(solid lines). Experimental setup was performed as described above.BMC Chemical Biology 2009, 9:3 http://www.biomedcentral.com/1472-6769/9/3
Page 5 of 15
(page number not for citation purposes)
immobilised cyclic nucleotide analog was affected by (i)
the exchange of the exocyclic oxygen to a sulphur in the
immobilised cAMP analog, (ii) the chosen linker of the
cAMP analog and (iii) the R-subunit isoform. In general,
dissociation in the presence of cGMP was slower for con-
ventional cAMP analogs compared to the newly designed
Sp-cAMPS analogs. When comparing dissociation from
all Sp-cAMPS analogs, a slower dissociation was observed
from the 2-substituted analog (Fig. 2E) than from the 8-
substituted analog (Fig. 2C, D). Among the R-subunit iso-
forms, RIIα displayed the slowest dissociation from all
five analog surfaces tested.
Generally, fast binding to the affinity matrix as well as
rapid and complete dissociation under elution conditions
are preferred for purification, without the dissociation of
protein from the affinity matrix under washing condi-
tions. From the observed elution patterns, Sp-8-AEA-
cAMPS was considered the best candidate for efficient elu-
tion of hRIα (Fig. 2C, F), especially when compared to 8-
AHA-cAMP and 8-AEA-cAMP which conventionally have
been employed (Fig. 2A, B) [18,27-29]. Panels A and B
(Fig. 2) clearly demonstrate that the RIβ and RIIα dissoci-
ate rather slow from the non Sp-cAMPS analogs, even in
the presence of cGMP. In general, for the R-subunit iso-
forms RIβ, RIIα and RIIβ, the dissociation with cGMP is
fast and almost identical for the 8-substituted cAMPS ana-
logs.
As a consequence of the high surface ligand density the
association and dissociation patterns of the R-subunits to
the immobilised cAMP analogs were severely affected by
mass transfer limitations. These limitations are due to
depletion of the analyte (here the R-subunits) being in
close proximity to the sensor surface during association,
thus prohibiting the quantitative analyses of association
and dissociation kinetics. Furthermore, rebinding effects
in the dissociation phase are intensified by the presence of
four cAMP binding sites per R-subunit dimer [30-32].
Still, the high surface density of cAMP analogs on the sen-
sor surface very well represents the situation that is occur-
ring on the agarose beads during binding and elution.
Purification of the R-subunit isoforms using Sp-cAMPS 
agaroses
The analogs tested in SPR (8-AEA-cAMP, 8-AHA-cAMP,
Sp-8-AEA-cAMPS, Sp-8-AHA-cAMPS and Sp-2-AHA-
cAMPS) were coupled to agarose beads using NHS chem-
istry (Fig. 3). Bacterial cell lysate containing overexpressed
RIα was incubated with each analog coupled to agarose (a
representative purification procedure with Sp-8-AEA-
cAMPS is shown in Fig. 4A). After several washing steps
were performed, no notable dissociation of the RIα subu-
nit from the agarose was detected. Elution of the protein
with 10 mM cGMP resulted in a protein fraction contain-
ing highly pure and active R-subunit as determined by
SDS-PAGE and spectrophotometric activity assay [33],
yielding 12 mg protein per approximately 400 μL of agar-
ose slurry. Only little additional protein could be eluted
subsequently with cAMP, still leaving some protein on the
agarose beads (Fig. 4A).
cGMP elution from the other two agaroses (Sp-8-AHA-
cAMPS and Sp-2-AHA-cAMPS) resulted in half the
amount of purified PKA R-subunit (7.2 mg protein per
approximately 400 μL of agarose slurry, Fig. 4B) when
compared to the yield from the Sp-8-AEA-cAMPS agarose.
Furthermore, hRIα could only be partially eluted from the
Sp-8-AHA-cAMPS agarose with 10 mM cAMP, while leav-
ing a significant amount of protein on the beads, thus
indicating that RIα binds too tight to this analog and
therefore can not be used for this affinity purification pro-
cedure. Additionally, both the Sp-2-AHA-cAMPS and Sp-
8-AHA-cAMPS agarose showed a 25 kDa protein coeluted
with cGMP, it was identified by mass spectrometry (MS)
as  E. coli Chloramphenicol Acetyltransferase which is
abundant in the BL21 (DE3) Codon Plus RIL strain (Fig.
4B).
Thus, from the three affinity resins tested, only Sp-8-AEA-
cAMPS fulfils and exceeds all necessary requirements for
Coupling of cyclic nucleotides to a solid support Figure 3
Coupling of cyclic nucleotides to a solid support. Representative scheme showing synthesis and coupling of Sp-8-AEA-
cAMPS to NHS-activated agarose beads (Affi-Gel® 10, BIO-RAD). For details of synthesis and coupling see Methods section.
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Figure 4 (see legend on next page)
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improved affinity purification when compared to conven-
tional 8-AEA- or 8-AHA-cAMP agarose chromatography
[18] and thus appears to be the best option for isolating
large quantities of pure and active RIα.
Comparison of conventional agaroses 8-AHA-cAMP and 8-
AEA-cAMP with Sp-8-AEA-cAMPS
The Sp-8-AEA-cAMPS resin as well as the conventional
agaroses 8-AHA-cAMP and 8-AEA-cAMP were all tested
via small scale purification with all four R-subunit iso-
forms, namely RIα, RIβ, RIIα and RIIβ. The protein yields
eluted first with cGMP and then subsequently in a second
elution step with cAMP are displayed in Fig. 5. As a control
the cAMP elution was performed according to Diller et al.
[18]. All R-subunit isoforms were obtained in a pure and
active form as determined by a spectrophotometric assay
[33]. Since the highest overall yield of the respective R-
subunit was obtained using Sp-8-AEA-cAMPS agarose,
this amount was set as the 100% reference point (Fig. 5A).
Interestingly, mild elution of RIα subunit with cGMP
from the Sp-8-AEA-cAMPS agarose is nine times more effi-
cient than the cGMP elution from the 8-AEA-cAMP agar-
ose. Furthermore, a fourfold higher yield was obtained
from the cGMP elution only using the Sp-cAMPS agarose
than from combining both elution steps (cGMP and
cAMP) employing 8-AEA-cAMP together. Purification of
RIα with 8-AHA-cAMP agarose was even less efficient than
using 8-AEA-cAMP (Fig. 5B). Still, the amount of RIβ, RIIα
and RIIβ isoforms eluted from our newly designed Sp-8-
AEA-cAMPS agarose was a minimum of 40% greater than
from the conventional agaroses.
In a further experiment all four R-subunit isoforms were
purified with the Sp-8-AEA-cAMPS agarose (data not
shown). The purification of RIα and RIIα isoforms
resulted in 12 mg protein per liter expression media. For
RIβ and RIIβ isoforms 5 mg and 3 mg protein were puri-
fied respectively. All affinity purified proteins were veri-
fied by MS (data not shown). The entire purification
procedure of each R-subunit isoform was completed
within 8 h.
Binding of the PKA holoenzyme complex to agonist and 
antagonist
Based on the purification strategy described above, novel
cAMP derivatives with antagonist properties were
designed to analyse the PKA holoenzyme (R2C2) complex
and target physiological interaction partners via a chemi-
cal proteomics approach. Only cAMP analogs derived
from the lead structure Rp-cAMPS (replacement of the
equatorial exocyclic oxygen of the cyclic phosphate, Fig.
1A right, 1C) have been shown to act as PKA-antagonists
[17,34-36], whereas the Sp-cAMPS analogs and cAMP
itself act as agonists (Fig. 1A left, 1B). The general assump-
tion that Rp-cAMPS binds to the R-subunit in the intact
PKA holoenzyme thus preventing complex dissociation
[37] was addressed by a combination of SPR binding anal-
ysis and Mass spectrometry (BIA-MS).
Therefore the antagonist Rp-8-AHDAA-cAMPS (for chem-
ical structure see Fig. 1C) and the agonist 8-AHA-cAMP
were covalently coupled to two sensor surfaces on a single
CM5 sensor chip. 250 nM of each, PKA holoenzyme
(R2C2), free R-subunit and C-subunit were injected to
both sensor surfaces. Fig. 6A shows the resulting binding
curves for type I holoenzyme. Maximum binding signals
of 17,000 and 6,900 RU on the antagonist and on the ago-
nist surfaces were observed, respectively. These difference
in the binding signals indicates that the entire holoen-
zyme complex is captured to the antagonist surface
whereas on the agonist surface only the free R-subunit is
bound, since the immobilised agonist causes holoenzyme
dissociation and release of the C-subunit. Hence, these
differences in binding signals reflect the mass difference
between the holoenzyme complex (R2C2) and the free R-
subunit (R2). A control experiment was performed, inject-
ing free R-subunit over both surfaces and similar binding
signals of approximately 5,300 RU each were obtained for
the agonist as well for the antagonist surface (Fig. 6A).
Furthermore, binding signals to the agonist surface using
free R-subunit and the PKA holoenzyme complex were in
the same range, again indicating that the holoenzyme dis-
sociates when interacting with the agonist surface. As an
Purification of hRIα subunit with different Sp-cAMPS analog agaroses analysed by SDS-PAGE Figure 4 (see previous page)
Purification of hRIα subunit with different Sp-cAMPS analog agaroses analysed by SDS-PAGE. (A) crude: total cell 
extract of E. coli BL21 DE3 Codonplus RIL with overexpressed hRIα at 52 kDa; supernatant: soluble fraction of bacterial lysate 
after French Press and centrifugation; pellet: insoluble fraction; sup agarose: unbound protein after incubation with Sp-8-AEA-
cAMPS agarose; wash agarose: aliquot after 6 washing steps with buffer B; elution cGMP and elution cAMP: elution with 10 mM 
cGMP and subsequently with 10 mM cAMP, respectively; wash agarose: aliquot after 6 washing steps with buffer B; agarose 
beads after elution: remaining protein on the agarose beads after the two elution and washing steps. M: molecular weight 
marker (Page-Ruler Unstained Protein Ladder, Fermentas). (B) Total cell extract of E. coli BL21 DE3 Codonplus RIL with over-
expressed hRIα was incubated with Sp-2-AHA-cAMPS and Sp-8-AHA-cAMPS, respectively, and eluted with cGMP (10 mM, 
lane 1 and 4) and subsequently with cAMP (10 mM, lane 2 and 5). Only a low amount of protein was left on Sp-2-AHA-cAMPS 
agarose after elution with cAMP (lane 3), whereas significant amounts of R-subunit remained on Sp-8-AHA-cAMPS agarose 
(lane 6). Asterisk indicates Chloramphenicol Acetyltransferase from E. coli BL21 (DE3) Codon Plus RIL as identified by MS.BMC Chemical Biology 2009, 9:3 http://www.biomedcentral.com/1472-6769/9/3
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Improvements on cAMP analogs for the purification of all R-subunit isoforms Figure 5
Improvements on cAMP analogs for the purification of all R-subunit isoforms. Comparison of the protein yield 
eluted from the agarose with cGMP (red bars) followed by cAMP (blue bars) indicated on the plot. Data were normalised to 
the total protein yield from both elution steps using Sp-8-AEA-cAMPS agarose as determined by BCA assay. The lower panel 
shows a SDS-PAGE of samples from each elution fraction (equal volumes of original fractions, cGMP elution red framed, cAMP 
elution blue framed). M: molecular weight marker (Page-Ruler Unstained Protein Ladder, Fermentas).BMC Chemical Biology 2009, 9:3 http://www.biomedcentral.com/1472-6769/9/3
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Rp-cAMPS analogs bind the intact PKA holoenzyme complex Figure 6
Rp-cAMPS analogs bind the intact PKA holoenzyme complex. The entire PKA type I holoenzyme complex (R2C2) 
binds highly specific to Rp-8-AHDAA-cAMPS as demonstrated by SPR (A), BIA MS (B) as well as affinity purification followed by 
SDS-PAGE (C) and Western blot analysis (D). (A) SPR binding pattern of type I holoenzyme, hRIα and Cα (as indicated, 250 
nM each) on antagonist (Rp-8-AHDAA-cAMPS) and agonist (8-AHA-cAMP) surfaces. Measurements were performed in buffer 
A containing 0.005% P20, 1 mM ATP and 10 mM MgCl2 at a flow rate of 5 μL/min. (B) BIA-MS: SDS-PAGE analysis of protein 
recovered from the experiments depicted in (A). Type I holoenzyme, R-subunit and C-subunit were injected to the agonist and 
antagonist surfaces as described and were eluted with 0.2% SDS after a 4 min wash step. The eluted material from 15 repetitive 
runs was pooled and analysed by SDS-PAGE, MS and Western blot analysis (not shown). C-subunit (42 kDa) and R-subunit 
hRIα (50 kDa) are indicated. M: molecular weight marker (Page-Ruler, unstained protein ladder, Fermentas). (C) Binding of 
PKA type I holoenzyme complex (R2C2, left panel), free C-subunit (center panel) and free R-subunit (right panel) to antagonist 
agarose (Rp-8-AHA-cAMPS, 600 pmoles, for chemical structure see Fig. 1C) determined with SDS-PAGE. (D) Immunoblot 
analysis of SDS gels from panel (C) using anti-C-subunit antibody.
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additional control C-subunit alone was injected over both
analog surfaces. No binding was observed, demonstrating
that the C-subunit does not contribute to the binding sig-
nal.
To prove that the intact holoenzyme complex was bound
to the antagonist sensor surface a BIA MS experiment was
performed (Fig. 6A, B). 250 nM of each, PKA holoenzyme
(R2C2), free R-subunit and C-subunit were injected and
after a 4 min wash, the sensor surface was incubated with
0.2% SDS. Proteins bound to the nucleotide surface were
eluted using the microrecovery function (Biacore 3000
Control Software 4.1) and the content of 15 subsequent
elutions was subjected to SDS-PAGE (Fig. 6B), displaying
two distinct bands. These bands correspond to R- and C-
subunits, as identified by LC-ESI MS/MS and Western blot
analysis (data not shown). Both, R- and C-subunit, were
detected in equal amounts according to Coomassie stain-
ing (Fig. 6B), strongly supporting the hypothesis that
functionally intact holoenzyme complex (R2C2) was
bound to the antagonist surface and subsequently eluted.
For a control the same amount of holoenzyme was also
injected to the agonist surface and analysed as described
above. Only R-subunit, but no C-subunit, could be
detected by SDS-PAGE (Fig. 6B), MS and Western blot
analysis (data not shown).
Based on the BIA-MS results (Fig. 6B), the antagonist was
coupled to agarose beads via NHS chemistry (Fig. 3).
These beads were then incubated with purified holoen-
zyme complex. Samples of each step of the pull down
experiment were analysed via a SDS-PAGE (Fig. 6C) as
well as analysed by Western blot with an anti-C-subunit
antibody (Fig. 6D), proving that Rp-cAMPS derivatised
agarose provides an extremely valuable tool for holoen-
zyme purification. An additional control was performed
with free R- and C-subunit. Both were incubated with the
antagonist beads and then analysed with SDS-PAGE. Only
the R-subunit but not C-subunit was detected verifying
the BIA-MS results.
Targeting the PKA interactome from pig brain using 
agonist and antagonist agaroses
In a proof of principle experiment agonist (Sp-8-AEA-
cAMPS) and antagonist agarose (Rp-8-AHDAA-cAMPS)
were incubated with pig brain lysate in order to investi-
gate, if endogenously expressed R-subunit and PKA
holoenzyme can be pulled out of biological material.
After incubation of the soluble protein fraction with the
affinity resins, the beads were washed six times and the
bound proteins were subsequently eluted with 20 mM
cAMP and analysed by SDS-PAGE (Fig. 7).
Using the agonist as affinity reagent, all four R-subunit
isoforms were pulled from pig brain lysate. When using
the antagonist, additionally all major C-subunit isoforms
(Cα, Cβ and Cγ; Fig. 7) were identified based on MS (data
not shown). In addition to the PKA subunits other distinct
sets of proteins were pulled out from pig brain tissue using
either agonist or antagonist agaroses (Bertinetti et al. in
preparation). This indicates, that functional complexes of
cAMP interactome can be pulled out of tissue lysates with
these new chemical tools, proving the opportunity for the
discovery of additional components of the cAMP signal-
ling pathway.
Discussion
During the last 30 years several approaches have been
used to selectively purify fully functional R-subunit iso-
forms of PKA, either endogenous from animal tissues [6]
or recombinantly expressed in bacteria [38]. Most purifi-
Affinity enrichment of components of the cAMP-pathway  using agonist and antagonist agaroses Figure 7
Affinity enrichment of components of the cAMP-
pathway using agonist and antagonist agaroses. Pro-
teins from pig brain tissue were enriched using agonist (Sp-8-
AEA-cAMPS) and antagonist (Rp-8-AHDAA-cAMPS) agar-
oses and subsequently eluted with cAMP. Fractions were 
separated on a 12% SDS-PAGE. supernatant: soluble protein 
fraction of pig brain after lysis, filtration and centrifugation; 
agonist/antagonist: protein eluted from the agonist/antagonist 
agarose with 25 mM cAMP. C-subunits (42 kDa), R-subunits 
RI (50 kDa) and RII (52 kDa) subunits are indicated, each 
identified by MS (data not shown). M: molecular weight 
marker (Page-Ruler, unstained protein ladder, Fermentas).
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cation strategies have been based on ion exchange chro-
matography. There were also early attempts to use cAMP
analogs linked via the N6 or C8 position of the adenine
ring to an agarose matrix for affinity purification of R-sub-
units from several tissues [5]. In most cases, however, the
affinity of the R-subunit to the various cAMP analogs used
was too high to subsequently and successfully elute the
protein efficiently. Only under harsh conditions could the
R-subunit be removed from the matrix either by one of the
two procedures: 7 M urea [6,39] or cAMP elution at ele-
vated temperatures [23,38]; while still yielding not only
less protein than using ion exchange chromatography but
also protein that was insoluble and/or proteolytically
degraded [26]. In order to increase the yield of nucleotide-
free and highly active R-subunit attempts to use fusion
tags for purification [40-42]. However, fusion tags to the
N-terminus as well as to the C-terminus of the R-subunit
turned out to be problematic. Modifications of the N-ter-
minus can interfere with R-subunit dimerisation and
binding of A kinase anchoring proteins [43]. Since fusion
tags on the C-terminus are located in close proximity to
the cAMP binding domains, the cyclic nucleotide binding
properties can be affected. Cleavage of the tag is an addi-
tional purification step which may lead to a loss of protein
as well as cause additional proteolytic products.
We synthesised 3 different Sp-cAMPS analogs (Sp-8-AEA-
cAMPS, Sp-8-AHA-cAMPS, Sp-2-AHA-cAMPS) and charac-
terised the binding to all four R-subunit isoforms in direct
interactions studies using SPR. Subsequently these ago-
nists were coupled to solid supports and used for affinity
purification of recombinantly expressed R-subunits. All
three analogs displayed superior purification strategies
when compared to conventional cAMP analogs (8-AEA-
cAMP, 8-AHA-cAMP).
Using Sp-8-AEA-cAMPS agarose it is now possible to
obtain large yields of active and nucleotide-free R-subunit
without the use of denaturants. This is especially impor-
tant since remaining nucleotide in the CNB domain
would interfere with subsequent studies. Furthermore
decreased stability of Urea unfolded and refolded protein
occurs [44].
In general, affinity reagents, addressing a specific subset of
proteins or protein complexes, are of growing importance
for many applications in proteomics. This includes
enrichment of proteins or subcellular components as well
as removal of unwanted cell debris subcellular compo-
nents, proteins and metabolites. Therefore, our described
cAMP analogs not only provide a highly selective tool as
an affinity material for purification of PKA R-subunits, but
can also serve as a tool that particularly targets the cAMP
sub-proteome (Bertinetti et al. in preparation). Here we
can demonstrate that components of cAMP signalling
pathways were selectively complexed with their physio-
logical interaction partners thus demonstrating that phos-
phorothioate cAMP analog agaroses are extremely
valuable for comparable chemical proteomics studies.
Furthermore, phosphorothioate cAMP analogs provide an
additional advantage as they were shown to be highly sta-
ble against phosphodiesterase activity [45] and are there-
fore well suited for use with cellular lysates.
In a recent approach, Scholten et al. [24] used conven-
tional cyclic nucleotide agaroses to pull out components
of the cGMP/cAMP interactome from rat heart tissue in
order to identify cyclic nucleotide binding proteins and
their interaction partners. Since elution with cAMP from
the 8-AEA-cAMP agarose was not sufficient for subsequent
MS analysis, those studies had to be performed with mate-
rial that was obtained by boiling the incubated agarose
beads in SDS loading buffer. With the newly designed Sp-
and Rp-cAMPS agaroses described here, specific binding
and elution of cAMP binding proteins and a reduction of
false positives can be achieved since elution with cAMP
can be considered as an additional purification step. The
use of these novel tools now enables us to also pull out
interaction partners of intact holoenzyme, which is espe-
cially important for identification of novel interaction
partners of the C-subunits of PKA such as the recently
described A-kinase interacting proteins (AKIPs, [46]) in
the holoenzyme form.
Conclusion
Novel cAMP analogs based on phosphorothioate were
optimised in an iterative approach combining design,
synthesis and direct SPR binding studies. After coupling to
a solid support, two sets of chemical binders were tested
for highly efficient purification procedure of all isoforms
of PKA R-subunit. Sp-8-AEA-cAMPS was identified as the
most valuable tool for purification purposes, yielding mil-
ligram amounts of both highly pure and active R-subunit
within 8 h. Furthermore, Sp- and Rp-cAMPS derived ana-
logs have the potential to be employed in a chemical pro-
teomics approach targeting distinct cAMP sub-proteomes.
Methods
Chemicals
All chemicals used were of the purest grade available and
were obtained either from Sigma-Aldrich (Seelze), Roth
(Karlsruhe) or Applichem (Darmstadt). The following
cAMP-analogs were synthesised by Biolog LSI (Bremen):
8-AHA-cAMP, 8-AEA-cAMP, Sp-cAMPS, Sp-8-AHA-
cAMPS, Sp-2-AHA-cAMPS, Sp-8-AEA-cAMPS, Rp-cAMPS,
Rp-8-AHA-cAMPS, Rp-8-AHDAA-cAMPS. A representative
scheme with synthesis and coupling of Sp-8-AEA-cAMPS
to agarose beads is provided in Fig. 3.BMC Chemical Biology 2009, 9:3 http://www.biomedcentral.com/1472-6769/9/3
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Synthesis of cyclic nucleotide derivatives and coupling to 
agarose
All cAMP- and ω-aminoalkyl-substituted Sp-cAMPS ana-
logs (for chemical structure see Fig. 1B) were synthesised
as described [22,47] with some minor modifications. Typ-
ically, 100 μmoles of (Sp)-8-Br-cAMP(S), (Sp)-2-Cl-
cAMP(S) or (Rp)-8-Br-cAMP(S) (Biolog) and 1,000
μmoles of 1,ω-diaminoalkan (Fluka) were dissolved in 10
mL water and refluxed until no starting material was
detectable by HPLC analysis (first step in the reaction
pathway Fig. 3). The reaction mixtures were neutralised
with diluted HCl, concentrated by rotary evaporation
under reduced pressure, and subsequently purified by
means of semi-preparative reversed phase HPLC (YMC
ODS-A 120–11, YMC). The column was washed with 100
mM NaH2PO4, pH 7, followed by water. Each cAMP(S)
analog was eluted with a gradient from 100% water to
100% acetonitrile. The product containing fractions were
collected and evaporated under reduced pressure to
obtain 8-AHA-cAMP, 8-AEA-cAMP, Sp-8-AHA-cAMPS, Sp-
8-AEA-cAMPS, Sp-2-AHA-cAMPS and Rp-8-AHDAA-
cAMPS in yields of 60–80% with purities > 99% (by
HPLC). The structure of each cAMP(S) analog was con-
firmed by UV/VIS spectrometry and FAB/MS or ESI/MS
analysis.
cAMP(S) analogs were coupled to NHS-activated agarose
beads (Affi-Gel® 10, BIO-RAD) according to the manufac-
turer's instructions (Fig. 3). Briefly, 6.6 μmoles of
cAMP(S) analog and 7.26 μmoles ethyldiisopropylamine
were added per mL settled gel, suspended in DMSO. Reac-
tion mixture was carefully shaken for 2–18 h at ambient
temperature until no further consumption of starting
material was detectable by analytical HPLC monitoring.
Any unreacted NHS-groups of the agarose gels were
blocked by addition of 20 μmoles ethanolamine per mL
settled gel by incubation for 1 h. After filtration and mul-
tiple washing with subsequently 2 × 25 mL 20% ethanol,
2 × 25 mL H2O and 2 × 25 mL 30 mM NaH2PO4, pH 7,
each agarose gel was stored in 30 mM NaH2PO4, 1%
NaN3, pH 7 at 4°C. Ligand densities were 6 μmoles/mL 8-
AHA-cAMP, 6 μmoles/mL 8-AEA-cAMP, 4 μmoles/mL Sp-
8-AEA-cAMPS agarose, 5 μmoles/mL Sp-8-AHA-cAMPS
agarose, 6 μmoles/mL Sp-2-AHA-cAMPS agarose and 6
μmoles/mL Rp-8-AHDAA-cAMPS agarose.
Direct binding studies of Sp-cAMPS analogs using SPR
Sp-2-AHA-cAMPS, Sp-8-AEA-cAMPS, Sp-8-AHA-cAMPS
(for chemical structures see Fig. 1B), 8-AHA-cAMP and 8-
AEA-cAMP were dissolved in 100 mM HEPES-KOH pH 8
by cautious heating (max. 70°C) and filtered. The concen-
trations of the stock solutions were determined via their
respective extinction coefficient. CM5 sensor chip surfaces
(research grade, Biacore AB) were activated for 10 min
with NHS/EDC according to the manufacturer's instruc-
tions (amine coupling kit, Biacore AB). The analogs (3
mM) were injected for 7 min (running buffer: 100 mM
HEPES, pH 8). Deactivation of the surface was performed
with 1 M ethanolamine-HCl, pH 8.5. Each flow cell was
activated, coupled and deactivated individually with a
flow rate of 5 μL/min at 20°C. A reference cell (Flow cell
1) was activated and deactivated without ligand immobi-
lisation.
All interaction analyses were performed at 20°C in 150
mM NaCl, 20 mM MOPS, pH 7 (buffer A) containing
0.005% (v/v) surfactant P20, using a Biacore 2000 instru-
ment (Biacore AB). Binding analyses were performed by
injection of 100 nM hRIα, hRIβ, hRIIα and rRIIβ (all pro-
teins were purified classically by DEAE cellulose chroma-
tography [48]) at a flow rate of 10 μL/min. Association
and dissociation were monitored for 5 min and 10 min,
respectively. Dissociation was performed in buffer A con-
taining 0.005% P20 in the presence or absence of 3 mM
cGMP. The sensor surfaces were regenerated after each
binding cycle by two short injections of 3 M guanidinium
HCl. After subtracting the reference cell signal, binding
data were normalised (Fig. 2).
Purification of hRIα using Sp-cAMPS agaroses
Bacterial cells overexpressing R-subunit were lysed using a
French Pressure Cell (Thermo Electron) in lysis buffer
containing 20 mM MOPS pH 7, 100 mM NaCl, 1 mM β-
mercaptoethanol, 2 mM EDTA and 2 mM EGTA (buffer
A). The crude lysate was centrifuged at 27,000 g for 30 min
at 4 C. Three different Sp-cAMPS agaroses (Sp-8-AHA-
cAMPS, Sp-8-AEA-cAMPS and Sp-2-AHA-cAMPS agarose)
were tested side by side in a one step purification strategy.
1.2 μmoles of coupled analog were used for each purifica-
tion, corresponding to approximately 400 μL of agarose
slurry. 12 mL supernatant from 500 mL bacterial culture
were incubated with the respective affinity matrices. Bind-
ing was carried out in a batch format by gently rotating
over night at 4°C. After washing the agarose seven times
with 1.25 mL lysis buffer each, the protein was eluted with
1.25 mL of 10 mM cGMP in buffer B (buffer A plus 1 mM
β-mercaptoethanol) by gentle rotation at 4°C for 1 h fol-
lowed by an elution using 10 mM cAMP in buffer B
instead of cGMP. Excess of nucleotide was removed using
a PD10 gel filtration column (Amersham Pharmacia).
cGMP bound to the cyclic nucleotide binding pockets was
removed by extensive dialysis against buffer B.
The purification strategy of RIβ with Sp-8-AEA-cAMPS fol-
lows in principle the procedure described for RIα.
Purification of type II R-subunits using Sp-8-AEA-cAMPS 
agarose
The purification strategy of RII isoforms follows the pro-
cedure described for hRIα except cell lysis was performedBMC Chemical Biology 2009, 9:3 http://www.biomedcentral.com/1472-6769/9/3
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in buffer containing 20 mM MES pH 6.5, 100 mM NaCl,
5 mM EDTA, 5 mM EGTA and 5 mM β-mercaptoethanol
(buffer C) including the protease inhibitors Leupeptin
(0,025 mg/100 mL, Biomol), TPCK and TLCK (each 1 mg/
100 mL, Biomol). After cell lysis, the soluble protein frac-
tion was incubated in a batch format with Sp-8-AEA-
cAMPS agarose (1.4 μmol analog). The agarose was
washed twice with 10 mL buffer D (20 mM MES pH 7, 1
M NaCl, 5 mM β-mercaptoethanol) and subsequently
with buffer C containing protease inhibitors. Two elution
steps were performed with 1 mL 25 mM cGMP in buffer C
and exchanged to 20 mM MES pH 6.5, 150 mM NaCl, 2
mM EDTA, 2 mM EGTA and 1 mM β-mercaptoethanol
using a PD10 column (Amersham).
Compared purification of all R-subunits using different 
cAMP analog agaroses
The side by side comparison of Sp-8-AEA-cAMPS, 8-AHA-
cAMP and 8-AEA-cAMP for purification was performed as
described for the RI and RII purification. Crude lysate
from one litre expression culture was divided into three
equal aliquots and incubated in a small scale experiment
with 100 μL of the respective agaroses. The cGMP elution
was followed by a second elution step with 40 mM cAMP
at room temperature for 30 minutes according to [18].
BIA-MS
Rp-8-AHDAA-cAMPS (for chemical structure see Fig. 1C)
and 8-AHA-cAMP were dissolved by cautious heating
(max. 60°C) in 100 mM Borate pH 8.5 with 20% DMSO
and 100 mM HEPES pH 8, respectively, filtered and cou-
pled to the sensor surface as described above. All microre-
covery experiments were performed in buffer A containing
10 mM MgCl2, 1 mM ATP with 0.005% (v/v) surfactant
P20 on a Biacore 3000 instrument. 250 nM PKA type I
holoenzyme (R2C2), free RIα subunit or C-subunit were
injected over the analog sensor surfaces in separate exper-
iments. The association phase was monitored for 5 min
followed by a 4 min washing step with running buffer.
Bound protein was eluted by incubating the sensor surface
with 0.2% SDS for 90 s and the eluted material was recov-
ered in a capped vial. The sensor surfaces were regenerated
by three subsequent injections of 3 M guanidinium HCl.
The recovered material from 15 repetitive cycles was
pooled and applied to a 12% SDS-PAGE [49] (Fig. 6B) for
protein identification via MS.
Fishing of PKA holoenzyme complex with Rp-cAMPS 
agarose
Purified recombinant mCα, hRIα and PKA holoenzyme
were each incubated with Rp-8-AHDAA-cAMPS agarose
(600 pmoles coupled analog, for chemical structure see
Fig. 1C) for 2 h at 4°C. The agarose was washed seven
times with 1 mL buffer E (buffer B containing 1 mM ATP
and 10 mM MgCl2). Protein was eluted with 1 mL 20 mM
cAMP in buffer E by gentle rotation at room temperature
for 1 h. The entire supernatant of each step was precipi-
tated with TCA and applied to SDS-PAGE (Fig. 6C). For
Western blotting, the samples were transferred to PVDF
membrane and immunoblotted with anti-PKA C-subunit
antibody (Santa Cruz Biotechnology, PKAα cat C-20) vis-
ualised by enhanced chemiluminescence (Fig. 6D).
Fishing of PKA holoenzyme complex with agonist and 
antagonist agarose from pig brain lysate
Fresh pig brain tissue was homogenised in buffer F (buffer
E in the presence of protease inhibitors (complete, EDTA
free, Roche), 2 mM NADH and 20 mM sucrose). After cen-
trifugation at 13,700 g for 25 min, the supernatant was fil-
tered and incubated with 150 μL agarose (corresponding
to 1 μmole of Sp-8-AEA-cAMPS or Rp-8-AHDAA-cAMPS)
over night at 4°C. The beads were washed six times with
1.5 mL buffer F. Elution was carried out with 1 mL of
buffer E containing 20 mM cAMP by gentle rotation at
room temperature for 1 h. All samples were precipitated
with TCA for SDS-PAGE (Fig. 7).
Biochemical characterisation of the proteins
The purification of the R-subunits was analysed by 12%
SDS-PAGE [49] unless otherwise noted and proteins were
stained with colloidal Coomassie Brilliant Blue dye mod-
ified after Neuhoff et al. [50-52]. After electrophoresis,
remaining SDS was removed by heating and rinsing in
distilled water. Overnight staining with 0.1% Coomassie®
Brilliant Blue G 250 in 5% aluminium sulphate octadec-
ahydrate and 2% phosphoric acid resulted in intense blue
bands with low background (Fig. 4, 5, 6, 7). Protein con-
centration was determined by a colorimetric assay using
BSA as a standard [53]. The biological activity of the pro-
teins was verified by a spectrophotometric phosphotrans-
ferase assay using the substrate peptide Kemptide
(LRRASLG, Biosynthan) according to Cook et al. [33].
Mass spectrometry analysis
Protein bands were excised from one-dimensional SDS-
PAGE [49] and digested in gel with trypsin according to
published procedures [54], modified by omitting all pre-
washing steps. After equilibrating in water, the gel pieces
(Fig. 4, 6B, 7) were excised and homogenised via centrifu-
gation (1,6000 g) through 10 μL pipet tips (MBP) and col-
lected in small reaction vials (CS-Chromatographie
Service). Destaining, reduction and alkylation were omit-
ted and 25 μL digestion buffer containing 50 mM
NH4HCO3, 100 ng/μL of trypsin (sequencing grade,
Promega) were added directly to the gel slurry and incu-
bated at 50°C for a minimum 1 h [55]. After a short cen-
trifugation the supernatants were diluted with 40 μL of
0.3% formic acid for analysis in a nanoLC-ESI-MS/MS
(nanoLC-Ultimate HPLC-system, LC Packings, DionexBMC Chemical Biology 2009, 9:3 http://www.biomedcentral.com/1472-6769/9/3
Page 14 of 15
(page number not for citation purposes)
coupled online to a linear ion trap mass spectrometer
4000 QTRAP™, Applied Biosystems), as described in
[56,57]. The MS/MS spectra were searched against a non-
redundant sequence database (MSDB) using MASCOT
(Matrix Science), version 1.9.05. Taxonomy was restricted
to mammals with variable modifications on deamidation
(NQ), myristoylation (N-Term. G), oxidation (M) and
phosphorylation (ST).
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